Table 2 |.

Variables associated with death-censored graft loss by univariate analysis

Variable	Hazard ratio	95% confidence interval	P
CI per 1-unit increase	1.28	1.19–1.37	<0.0001
CI ≥4 vs. CI <4	6.93	3.79–12.65	<0.0001
AI per 1-unit increase	1.09	0.96–1.24	0.19
AI ≥9 vs. AI <9	2.78	1.10–7.02	0.030
(AI + CI) per 1-unit increase	1.26	1.18–1.35	<0.0001
(AI + CI) ≥13 vs. (AI + CI) <13	4.99	2.97–8.38	<0.0001
cg score per 1-unit increase	1.54	1.26–1.88	<0.0001
(ci + ct) per 1-unit increase	1.48	1.29–1.71	<0.0001
cv score per 1-unit increase	2.34	1.74–3.15	<0.0001
TCMR grade 1A or higher	2.32	1.41–3.85	<0.0001
Active AMR vs. chronic active AMR	0.30	0.17–0.52	<0.0001
AMR type 2 vs. AMR type 1	2.21	1.23–3.96	0.008
Biopsy ≥84 mo vs. biopsy <84 mo	2.51	1.47–4.30	0.0008
Biopsy post-transplant time (per month)	1.009	1.005–1.014	0.0002
eGFR (per ml/min)a	0.958	0.943–0.972	<0.0001
eGFR (per 10 ml/min)a	0.649	0.557–0.756	<0.0001
ΔRIS >−2	4.00	2.33–7.14	<0.0001

AI, activity index; AMR, antibody-mediated rejection; cg, Banff chronic glomerulopathy score; ci, Banff interstitial fibrosis score; CI, chronicity index; ct, Banff tubular atrophy score; cv, Banff chronic vasculopathy score; eGFR, estimated glomerular filtration rate; ΔRIS, change in donor-specific antibody relative intensity sum score; TCMR, T cell–mediated rejection.

Type 1 AMR indicates persistent/rebound donor-specific antibody, whereas type 2 AMR indicates de novo donor-specific antibody.

Development of graft loss in patient groups was analyzed using the Kaplan-Meier method with the log-rank test to determine significance, and Cox proportional hazards models were used to determine hazard ratios and their 95% confidence intervals.

^aBased on 143 cases; other determinations based on 147.